Third Rock's Goldfinch bags rights to Takeda kidney disease drug 0 03.10.2019 14:36 Fiercebiotech.com Goldfinch Bio has secured the global rights to a peripherally restricted cannabinoid receptor 1 monoclonal antibody from Takeda. The Third Rock startup plans to file an IND for the treatment for rare and metabolic kidney diseases next year. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
